^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Lymphir (denileukin diftitox-cxdl)

i
Company:
Citius Oncology, Eisai
Drug class:
IL-2 stimulant
Phase 1/2
Haider Mahdi
Recruiting
Last update posted :
11/09/2023
Initiation :
09/30/2022
Primary completion :
12/01/2025
Completion :
12/01/2027
MSI • CD4 • IL2
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Lymphir (denileukin diftitox-cxdl)
Phase 1/2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
07/07/2023
Initiation :
06/09/2021
Primary completion :
12/01/2024
Completion :
12/01/2024
MYC
|
MYC expression
|
Kymriah (tisagenlecleucel-T) • Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)
Phase 3
Eisai Inc.
Completed
Last update posted :
12/12/2022
Initiation :
05/30/2013
Primary completion :
12/06/2021
Completion :
12/14/2021
IL2RA • IL2 • ISG20
|
Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)
Phase 2
Eisai Co., Ltd.
Completed
Last update posted :
07/15/2021
Initiation :
03/28/2016
Primary completion :
04/26/2019
Completion :
04/26/2019
IL2
|
Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)